In complementary work, a tumor cell line that was selected for resistance to immunotherapy upregulated AKT compared with sensitive wild-type cells, and this was associated with increased levels of BIRC2 and BIRC3, BCL-2 and BCL-XL [48]. This evidence concerns the gene BCL2L1 and neoplasm.